The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate

Clinical Therapeutics

Volumn 23, Issue 4, 2001, Pages 578-584

  Kaye, Clive M ^a   Allen, Ann ^a   Perry, Sheryl ^a   McDonagh, Margaret ^a   Davy, Maria ^a   Storm, Kevin ^b   Bird, Nicholas ^a   Dewit, Odile ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Amoxicillin clavulanate; Antibiotic; Pharmacokinetically enhanced; Pharmacokinetics

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CLAVULANATE POTASSIUM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BODY WEIGHT; CANDIDIASIS; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NORMAL HUMAN; PLASMA; STREPTOCOCCUS PNEUMONIAE;

EID: 0035005015     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80061-8     Document Type: Article

References (6)

1. Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use
2. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
3. Postantibiotic and postβ-lactamase inhibitor effects of amoxicillin plus clavulanate
4. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae